CTS will implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
CTS Dallas and Phoenix Labs successfully implemented WNV NAT testing on the Panther Testing Platform...
The CTS Medical Advisory Board recently agreed upon a revision to our standard testing algorithm thi...
CTS received notification from Sanochemia Pharmazeutika AG of their intent to immediately discontinu...
As a friendly reminder, airlines often change their routine flights and cargo hours for holidays. We...
Honor Your StaffCelebrate Lab Week, and honor yourself and your colleagues as a vital part of the la...